Osimertinib, a 3rd generation EGFR-TKI, is the appropriate second-line drug after acquisition of resistance to gefitinib, erlotinib, or afatinib if a rebiopsied resistant tumor proves the presence of an EGFR T790M secondary mutation [3]. Here, EGFR is linked to neoplasm.